All In MedTech

Device Trial Radar · NCT05574868

Rigicon Infla10® Three-Piece Inflatable Penile Prosthesis (ERASE ED)

Evaluation of the Rigicon Infla10® Three-Piece Inflatable Penile Prosthesis for the Treatment of Patients With Erectile Dysfunction

Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

182

Planned (sponsor's estimate)

Start

Jan 16, 2025

Primary completion

Aug 1, 2027

Study completion Aug 1, 2028

Sponsor

Lead sponsor
Rigicon, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Oct 12, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Male only, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the long-term safety and efficacy of the use of the Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis in patients with erectile dysfunction. This study follows patients implanted with the Rigicon Infla 10® Three-Piece Inflatable Penile Prosthesis for up to 3 years after implantation. This study will take approximately 6 months to enroll all subjects. (14 days, 6 weeks, 6 months, 12 months,18 months, 24 months, and 36 months, post-procedure. ) Subjects will be followed per protocol and institutional standard of care for ED and comorbidities.

Conditions

  • Erectile Dysfunction

Interventions

  • Rigicon Infla 10® Three-Piece Inflatable Penile ProsthesisDevice

    Treatment: Erectile dysfunction

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary safety outcome is the proportion of participants free from any device- or procedure-related adverse event of CTCAE Grade ≥2 through 12 months post-procedure, graded per CTCAE v6.0 and IPP-specific mapping.Time frame: 12 months
  2. The primary effectiveness endpoint is a binary "pass" or "fail" objective axial rigidity test, assessed at 12 months.Time frame: 12 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Wesley Hospital

    Auchenflower, Australia · Recruiting

  • Canberra Laparoscopic, Robotic & Laser Urology Centre

    Garran, Australia · Recruiting

  • Katelaris Urology

    Hornsby, Australia · Recruiting

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.